Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer, Hepatocellular Clear all
Recruiting Phase 2Phase 3 Interventional

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

NCT06007846
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis
Interventions
Namenda
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma

NCT00976898
View directory record Official record
Conditions
Liver Cancer
Interventions
Proton Beam Irradiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors

NCT00093444
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
lyso-thermosensitive liposomal doxorubicin, radiofrequency ablation
Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 27, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

NCT01101906
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma (HCC)
Interventions
OSI-906, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Los Angeles, California • New Orleans, Louisiana • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 27, 2026, 10:15 PM EDT
Recruiting Phase 1 Interventional

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

NCT07116486
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Radiopharmaceutical 18F-FSPG
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available

Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies

NCT01401907
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer, Gastric Cancer, Liver Cancer, Pancreatic Cancer
Interventions
early palliative care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

NCT03890731
View directory record Official record
Conditions
Solid Cancer
Interventions
BAY73-4506 (Regorafenib, Stivarga)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 27, 2026, 10:15 PM EDT
Completed No phase listed Observational

Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI)

NCT01234701
View directory record Official record
Conditions
Neoplasms
Interventions
Non-invasive Magnetic Resonance Imaging (MRI), Liver resection, Histopathology diagnosis of resected liver specimen
Other · Procedure
Lead sponsor
University of Zurich
Other
Eligibility
18 Years to 90 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 27, 2026, 10:15 PM EDT
Active, not recruiting Phase 3 Interventional

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

NCT03654053
View directory record Official record
Conditions
Cirrhosis
Interventions
Placebo Oral Tablet, Simvastatin 40mg
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
San Francisco, California • West Haven, Connecticut • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 27, 2026, 10:15 PM EDT
Terminated Phase 2Phase 3 Interventional

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

NCT00057382
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
T138067 intravenous, doxorubicin intravenous
Drug
Lead sponsor
Tularik
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Early Phase 1 Interventional

Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis

NCT03407001
View directory record Official record
Conditions
Cirrhosis
Interventions
Contrast-Enhanced Ultrasound, Sulfur Hexafluoride Lipid Microspheres, Ultrasound
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 27, 2026, 10:15 PM EDT
Recruiting Phase 1 Interventional

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

NCT06582017
View directory record Official record
Conditions
Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Interventions
QXL138AM Injection every 2 weeks by IV Infusion
Biological
Lead sponsor
Nammi Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Newport, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Pumitamig, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

NCT07636785
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer, Colorectal Cancer (CRC)
Interventions
VMD-102
Drug
Lead sponsor
VM Discovery, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available

Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases

NCT01528878
View directory record Official record
Conditions
Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
Interventions
Stereotactic Radiosurgery using the CyberKnife System.
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Early Phase 1 Interventional

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

NCT05250895
View directory record Official record
Conditions
BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions
18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 27, 2026, 10:15 PM EDT
Recruiting No phase listed Observational

Patient-Derived Xenografts to Reduce Cancer Health Disparities

NCT04410302
View directory record Official record
Conditions
Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm
Interventions
Biospecimen Collection
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Orange, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

NCT03318562
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hepatocellular Carcinoma
Interventions
eFT508
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Duarte, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

NCT00128596
View directory record Official record
Conditions
Liver Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 27, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028
View directory record Official record
Conditions
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 27, 2026, 10:15 PM EDT
Completed No phase listed Observational

National Registry and Blood Bank of Patients With Liver Cancer

NCT00482365
View directory record Official record
Conditions
Liver Cancer
Interventions
biologic sample preservation procedure, medical chart review, Patient interview
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 27, 2026, 10:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Breath Analysis Based Disease Biomarkers

NCT04341012
View directory record Official record
Conditions
Liver Diseases, Liver Cancer, COVID19
Interventions
Collection of breath sample
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 27, 2026, 10:15 PM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 27, 2026, 10:15 PM EDT